Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of SNN is 35 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation sugg
Buy
Sell